- Home
- QSI vs EYPT Comparison
QSI vs EYPT Comparison
Compare QSI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | EYPT |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | 145 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 1.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | QSI | EYPT |
|---|---|---|
| Price | $0.74 | $13.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.00 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 3.1M | 1.1M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $618.07 | $1,031.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $3.91 |
| 52 Week High | $3.10 | $19.11 |
Technical Indicators
Market Signals| Indicator | QSI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 46.16 |
| Support Level | N/A | $12.47 |
| Resistance Level | $1.11 | $14.54 |
| Average True Range (ATR) | 0.05 | 0.72 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.54 | 69.30 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.